A 96-year-old woman with moderate to severe dementia was admitted in acute delirium. According to her next of kin, the patient had been reporting generalized weakness for the last few days, and her appetite had decreased. The day before admission, she began having visual and auditory hallucinations.

At the time of admission, the patient was delirious and in moderate respiratory distress, with rapid shallow breathing and an oxygen saturation level of 88% on room air. Bilateral basilar crackles on inspiration and right-sided rhonchi were heard on auscultation. Her blood pressure was 140/75 mm Hg, her heart rate was 110 beats/min with a normal sinus rhythm, and her temperature was 37.2°C. The initial results of imaging and laboratory investigation were all normal, including a computed tomography scan of the head, chest radiographs, complete blood count with differential count, thyroid function tests, and serum levels of electrolytes, liver enzymes, amylase, lipase, cardiac enzymes, vitamin B₁₂, erythrocyte folate, iron, ammonia and alcohol. The results of her blood gas tests were normal except for a partial pressure of oxygen of 60. The results of Gram staining and culture of blood, urine and sputum samples were negative for bacteria. The results of urine toxicology screening were negative for opiates and benzodiazepines. Twelve-lead electrocardiography did not show evidence of acute coronary syndrome or arrhythmias. Empirical treatment with broad-spectrum antibiotics, including piperacillin-tazobactam and vancomycin, was started for suspected aspiration pneumonia.

Three days later, the patient’s mental status and respiratory distress were worse. Levofloxacin was added to the treatment to provide coverage for atypical bacteria. A neurology consultation was obtained to rule out a neurologic cause for the patient’s worsening mental status. Magnetic resonance imaging of the brain and electroencephalography were done, but neither showed acute neurologic pathology. We diagnosed metabolic encephalopathy secondary to underlying pneumonia.

According to social services, the patient owned a home where she and a relative had been living together for several years. The patient had been receiving nursing care and other services in her home. Home health care staff had suspected physical abuse of the patient, and as a result, the court had appointed a lawyer as the patient’s legal guardian. Given the change in the patient’s mental status and upon learning about the alleged physical abuse, we were concerned about possible foul play and repeated the urine toxicology screen. To our surprise, the results were positive for opiates. A system-wide investigation was undertaken to find the possible source of the opiates. No evidence was found that an opiate-containing medication had been administered to the patient since the time of admission, and the nursing staff ruled out medication error.

While searching the literature for information on possible false-positive urine screens for opiates, we found an article by Baden and colleagues, which reviewed the association between such false-positive results and fluoroquinolones, such as levofloxacin, when using enzyme immunoassay techniques. Our laboratory uses the SYNCHRON enzyme immunoassay for urine toxicology screening, with a laboratory cutoff level for opiates of 300 ng/mL (1050 nmol/L). To confirm whether the urine screen result was false positive, the same urine sample that had tested positive for opiates and a serum sample taken within an hour of the urine sample were sent to an outlying facility for a nonimmunologic, quantitative technique such as mass spectroscopy should be performed.
with azithromycin. One week later, the results of a repeat urine toxicology screen using the SYNCHRON enzyme immunoassay technique were negative for opiates. The patient’s symptoms gradually improved, and she was discharged to an extended care nursing facility.

Discussion

Enzyme immunoassay qualitative techniques for urine screening are commonly used because of their wide availability, lower cost and reduced testing time compared with nonimmunologic techniques. Fluoroquinolones, such as levofloxacin, are frequently prescribed for the treatment of both community- and hospital-acquired infections. When enzyme immunoassay techniques are used for urine screening, a false-positive result for opiates in a patient taking levofloxacin may lead to erroneous clinical decisions and inadvertent litigation.1-4 Baden and colleagues found that even a single dose of levofloxacin can interact with the enzyme immunoassay screening test, and the false-positive result for opiates can remain positive for 24 hours or more depending on the clearance of levofloxacin from the system. In their study involving six healthy volunteers, the researchers tested the cross-reactivity of 13 different quinolones with five commercial opiate screening assays. Nine of the quinolones caused a false-positive result in at least one of the assays. Levofoxacin, ofloxacin and pefloxacin most consistently caused false-positive results.1

Fluoroquinolones are not the only medications that may cross-react with enzyme immunoassay urine screening tests. Others include commonly used over-the-counter medications such as ibuprofen and dextromethorphan (Table 1).5 Venlafaxine, selegiline, oxaprozin and rifampin also have the potential to interact with these tests. Depending on the interaction, the test result may be false positive for benzodiazepines, opiates, amphetamines, barbiturates, cannabinoids or phencyclidine (PCP).

If a false-positive urine screen result is suspected, a quantitative test using nonimmunologic techniques, such as gas chromatography, mass spectroscopy or high-performance liquid chromatography, is necessary for confirmation.

This article has been peer reviewed.

Competing interests: None declared.

REFERENCES

1. Baden LR, Horowitz G, Jacoby H, et al. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA 2001;286:3115-9.
2. Staley CM, Cecil EI, Herriman MP. Gatifloxacin interference with opiate urine drug screen. Pharmacotherapy 2006;26:435-9.
3. Zacher JL, Givone DM. False-positive urine opiate screening associated with fluoroquinolone use. Ann Pharmacother 2004;38:1525-8.
4. Meatherall R, Dai J. False-positive EMIT II opiates from ofloxacin. Ther Drug Monit 1997;19:98-9.
5. Vincent EC, Zebelman A, Goodwin C, et al. Clinical inquiries. What common substances can cause false positives on urine screens for drugs of abuse? J Fam Pract 2006;55:893-4, 897.

Correspondence to: Dr. Qaiser Shafiq, Department of Internal Medicine, University of Toledo Medical Center, 3045 Arlington Ave., Toledo OH 43614, USA; qaiser.shafiq@utoledo.edu

Table 1: Cross-reactivity of commonly used medications in urine toxicology screening assays

| Drug identified in false-positive result | Medication responsible for result |
|----------------------------------------|----------------------------------|
| Amphetamine and methamphetamine       | Selegiline, camphor/menthol vapour inhaler |
| Barbiturate                            | Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen) |
| Benzodiazepine                         | Oxaprozin                        |
| Cannabinoid                            | Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen) |
| Opiate                                 | Fluoroquinolones (e.g., levofloxacin, ofloxacin and pefloxacin), rifampin |
| Phencyclidine                          | Venlafaxine, dextromethorphan   |

Source: Vincent et al.5